CRF Health

The Essential Guide to Electronic Informed Consent_FINAL

Issue link:

Contents of this Issue


Page 26 of 27

While there is little doubt that the future of obtaining informed consent in clinical trials will be via electronic methods, for busy sponsors and researchers who are finding themselves under greater pressure to bring new drugs to market within shorter timeframes and increasingly tight budgets, the introduction of yet another new technology could be seen as too much to take on. However, by integrating eConsent technology with existing platforms, researchers can remove the need for any additional technologies to be included in a trial's design, significantly reducing the burden and complexity for study teams, and promoting participant compliance and retention by driving better comprehension of a study's unique requirements. In a time when we are seeing an influx of technology across the clinical trials lifecycle, consolidating technologies and bringing complementary platforms together, wherever possible, makes sense. In addition, while the perceived costs of eConsent integration could be seen by some as a barrier, the potential to drive significant operational efficiencies, minimize regulatory risk, ensure participant comprehension and achieve long-term cost savings is clear. For further information and advice in making the switch, please contact CRF Health at or visit MAKING THE MOVE 25 © CRF HEALTH. ALL RIGHTS RESERVED. WWW.CRFHEALTH.COM

Articles in this issue

Links on this page

view archives of CRF Health - The Essential Guide to Electronic Informed Consent_FINAL